Cellebrite DI Ltd. (NASDAQ:CLBT) is one of the best growth stocks to buy for the next 20 years. On February 12, following the company’s solid Q4 2025 results, TD Cowen lowered its price target on Cellebrite to $23 from $25 and maintained a Buy rating. The firm cited market contraction as the reason for the reduction, despite the company reporting 21% growth in both annual recurring revenue and subscription revenue alongside a positive outlook for 2026. On the same day, Needham also lowered its price targ ...